We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High-Sensitivity Cardiac Troponin I Assay Validated

By LabMedica International staff writers
Posted on 20 Sep 2018
Myocardial infarction (MI), commonly known as a heart attack occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle. More...
The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.

The diagnosis of myocardial infarction requires two out of three components, history, electrocardiogram (ECG), and levels of certain enzymes. When damage to the heart occurs, levels of cardiac markers rise over time, which is why blood tests for them are taken over a 24-hour period.

Scientists at the University Hospital Basel (Basel, Switzerland) and their international colleagues enrolled 1,755 patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by two independent cardiologists including all clinical information twice.

The team used serial Troponin T-high sensitive assay for primary analysis; secondly, they used using High Sensitive Troponin-I for secondary analysis measurements. In addition they clinically applied high sensitivity cardiac troponin (hs-cTnI), which was measured at presentation, one hour and two hours.

AMI was the final diagnosis in 318 of 1,755 (18%) patients using the Roche-hs-cTnT-Elecsys for adjudication. The area under the curve (AUC) at presentation for Siemens-hs-cTnI-Centaur was 0.94 and comparable with 0.95 for Roche-hs-cTnT-Elecsys and 0.93 for Abbott-hs-cTnI-Architect. Applying the derived Siemens-hs-cTnI-Centaur 0/1-h algorithm to the validation cohort, 46% of patients were ruled out (sensitivity, 99.1%, and 18% of patients were ruled in, specificity, 94.1%. The Siemens-hs-cTnI-Centaur 0/2-h algorithm ruled out 55% of patients (sensitivity, 100%), and ruled in 18% of patients (specificity, 96.0%). Findings were confirmed in the secondary analyses using serial measurements of Abbott-hs-cTnI-Architect for adjudication.

The authors concluded that diagnostic accuracy and clinical utility of the novel Siemens-hs-cTnI-Centaur assay are high and comparable with the established hs-cTn assays. The study was published in August 2018 in the journal Clinical Chemistry.

Related Links:
University Hospital Basel


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.